APA (7th ed.) Citation

DS, V., M, R., E, G., HM, A., RW, N., J, S., . . . RL, S. (2026). Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO precision oncology, 10(7), e2600456. https://doi.org/10.1200/PO-26-00456

Chicago Style (17th ed.) Citation

DS, Veljovich, et al. "Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study." JCO Precision Oncology 10, no. 7 (2026): e2600456. https://doi.org/10.1200/PO-26-00456.

MLA (9th ed.) Citation

DS, Veljovich, et al. "Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study." JCO Precision Oncology, vol. 10, no. 7, 2026, p. e2600456, https://doi.org/10.1200/PO-26-00456.